Whalesbook
The steep decline in Dr. Reddy's Laboratories' quarterly profit underscores significant margin pressures that impacted its fourth fiscal quarter results. Profit after tax for Q4 FY26 plummeted 86% year-over-year to ₹221 crore, a sharp reversal from ₹1,587 crore in the prior year period. This dramatic fall was primarily fueled by a 90% year-over-year drop in profit before tax, which hit ₹199 crore.
Margin Compression Hurts Profitability
The core issue lies in the contracting gross margins. Gross profit for the quarter slumped 29% to ₹3,369 crore from ₹4,726 crore, pushing the gross profit margin down to 44.8% from 55.6% in the same quarter last year. This erosion in profitability persisted across segments, with Global Generics revenue down 13% and Pharmaceutical Services and Active Ingredients (PSAI) revenue down 5.7% year-over-year for the quarter.
Revenue and Expense Dynamics
While full-year revenues saw a modest 3% increase to ₹33,593 crore, the fourth quarter painted a weaker picture with revenues declining 12% year-over-year to ₹7,516 crore. Simultaneously, Selling, General & Administrative expenses rose 15% to ₹2,776 crore, further squeezing profitability. The company's EBITDA margin also compressed significantly, falling to 13.0% from 29.1% in Q4 FY25.
Full-Year Outlook and Dividend
Despite the weak quarter, Dr. Reddy's Laboratories maintained its annual revenue growth, albeit with a contraction in overall gross profit for FY26. The board has recommended a final dividend of ₹8 per equity share, signaling confidence in maintaining shareholder returns amidst operational challenges. The record date for this dividend is set for July 10, 2026.